公开(公告)号：US5831025A

公开(公告)日：1998-11-03

申请号：US637662

申请日：1996-04-29

申请人： Yoichi Ogata ,  Toshinobu Nouchi ,  Shinji Nakahira

发明人： Yoichi Ogata ,  Toshinobu Nouchi ,  Shinji Nakahira

IPC分类号： A61K38/46 ,  A61P7/02 ,  C07K1/18 ,  C07K1/22 ,  C07K14/755 ,  C12N9/64 ,  A61K35/16 ,  A61K38/16 ,  C07K17/14 ,  C12Q1/56

CPC分类号： C12N9/6464 ,  C12Y304/21069 ,  Y10S530/83 ,  Y10S530/856

摘要： A human Activated Protein C preparation with a high specific activity of 3500 U/mg or more and substantially free from thrombin or other proteases which can convert Protein C into Activated Protein C is provided. A process for preparing this human Activated Protein C, which involves, contacting a solution of human Activated Protein C, after activation of Protein C with thrombin or other activating protease, with a cation exchanger to allow for adsorption of both thrombin or another activating protease and Activated Protein C to the cation exchanger followed by elution of the human Activated Protein C alone.

摘要翻译： PCT No.PCT / JP94 / 01807 Sec。 371日期：1996年4月29日 102（e）日期1996年4月29日PCT 1994年10月27日PCT公布。 公开号WO95 / 11966 日期1996年5月4日提供具有3500U / mg以上的高比活性和基本上不含可将蛋白C转化成活化蛋白C的凝血酶或其它蛋白酶的人活化蛋白C制剂。 制备这种人活化蛋白C的方法，其涉及在将蛋白C与凝血酶或其它活化蛋白酶一起活化后将人活化蛋白C的溶液与阳离子交换剂接触以允许凝血酶或另一活化蛋白酶的吸附， 将活化的蛋白C转移至阳离子交换剂，然后单独洗脱人活化蛋白C。

公开(公告)号：US5814321A

公开(公告)日：1998-09-29

申请号：US758374

申请日：1996-11-29

申请人： Tokuji Miyahara ,  Kozo Takase ,  Koichi Saito ,  Yoko Kishimoto ,  Satoru Tokuyama

发明人： Tokuji Miyahara ,  Kozo Takase ,  Koichi Saito ,  Yoko Kishimoto ,  Satoru Tokuyama

IPC分类号： A61K39/39 ,  A61K45/00 ,  A61K9/107

CPC分类号： A61K39/39 ,  A61K2039/55566 ,  Y10S514/937 ,  Y10S514/938 ,  Y10S514/939 ,  Y10S514/943

摘要： A water-in-oil type oil adjuvant vaccine comprises 20 to 90% by weight of an oil phase A) which is in a liquid state at ordinary temperature; 0.5 to 30% by weight of an emulsifying agent comprising a non-ionic surfactant B) which is a partial ester derived from a polyhydric alcohol carrying at least three hydroxyl groups and a fatty acid and which is in a liquid state at 40.degree. C. and a polyoxyethylene (20 to 60 moles) hydroxy fatty acid triglyceride C); and 5 to 75% by weight of an aqueous phase D) containing a biologically acceptable and effective amount of antigens, and optionally E) 0.01 to 10% by weight of an amino acid or a salt thereof and 0.01 to 10% by weight of a non-reducing sugar or a sugar alcohol having at least 5 hydroxyl groups in the molecule. In addition, a water-in-oil-in-water type oil adjuvant vaccine comprises the foregoing water-in-oil type oil adjuvant vaccine as an internal phase and an outer aqueous phase F) comprising 0.2 to 20% by weight of an emulsifying agent which comprises a non-ionic surfactant and which has an overall HLB value of not less than 10. The oil adjuvant vaccines show a high ability to induce an antibody-production over a long period of time and are excellent in requirements for medicines such as stability and safety.

摘要翻译： 油包油型油佐剂疫苗含有20〜90重量％的油相A），其在常温下为液态; 0.5至30重量％的包含非离子表面活性剂B）的乳化剂，其为衍生自至少三个羟基和脂肪酸的多元醇的偏酯，并且在40℃处于液态。 和聚氧乙烯（20至60摩尔）羟基脂肪酸甘油三酯C）; 和5至75重量％的包含生物可接受和有效量的抗原的水相D），以及任选地E）0.01至10重量％的氨基酸或其盐和0.01至10重量％的 非还原糖或分子中具有至少5个羟基的糖醇。 此外，水包油包水型油佐剂疫苗包含上述油包水型油佐剂疫苗作为内相和外水相F），其包含0.2-20重量％的乳化剂 药物，其包含非离子表面活性剂，其总体HLB值不小于10.油佐剂疫苗显示出在长时间内诱导抗体产生的高能力，并且对药物如 稳定性和安全性。

公开(公告)号：US5811279A

公开(公告)日：1998-09-22

申请号：US905041

申请日：1997-08-01

申请人： Hiroshi Kaetsu ,  Jun Mizuguchi ,  Takayoshi Hamamoto

发明人： Hiroshi Kaetsu ,  Jun Mizuguchi ,  Takayoshi Hamamoto

IPC分类号： A61K38/48 ,  A61P7/04 ,  C12N9/74

CPC分类号： C12N9/6429 ,  C12Y304/21005

摘要： A method for activating prothrombin to thrombin is presented which comprises treating an aqueous solution containing prothrombin with polyethylene glycol in the presence or absence of the calcium salt. The method enables conversion of prothrombin to thrombin in the absence of thromboplastin and allows for preparation of thrombin on an industrially large scale from easily available starting materials.

摘要翻译： 提出了一种激活凝血酶原至凝血酶的方法，包括在存在或不存在钙盐的情况下，用聚乙二醇处理含有凝血酶原的水溶液。 该方法能够在不存在凝血激酶的情况下将凝血酶原转化为凝血酶，并允许在工业上大规模从容易获得的起始材料制备凝血酶。

公开(公告)号：US5785968A

公开(公告)日：1998-07-28

申请号：US24253

申请日：1993-03-01

申请人： Kazuhiko Kimachi ,  Hiroaki Maeda ,  Kiyoto Nishiyama ,  Sachio Tokiyoshi ,  Yukinobu Tohya ,  Takeshi Mikami

发明人： Kazuhiko Kimachi ,  Hiroaki Maeda ,  Kiyoto Nishiyama ,  Sachio Tokiyoshi ,  Yukinobu Tohya ,  Takeshi Mikami

IPC分类号： A61K38/00 ,  C07K16/10 ,  C12N15/13 ,  C12P21/08 ,  C07H21/04 ,  A61K39/395 ,  C07H16/00

CPC分类号： C07K16/1045 ,  A61K38/00

摘要： Anti-FCV (feline calicivirus) feline-type recombinant antibody effective for treatment, prevention and diagnosis of FCV infection and a gene fragment useful for preparation of said antibody are provided. Cell line 1D7 capable of producing a mouse monoclonal antibody having an excellent FCV-neutralizing activity was constructed and a gene fragment coding for the V region in charge of the FCV-specific binding of said antibody was obtained. This gene fragment and the gene coding for the constant region of the feline antibody are used to give a chimeric anti-FCV recombinant antibody. The obtained recombinant antibody is a novel antibody and is useful for the diagnosis, treatment and prevention of feline virus infections, particularly feline calicivirus infection, with high safety in administration into cats.

摘要翻译： 提供了有效治疗，预防和诊断FCV感染的抗FCV（猫杯状病毒）猫科动物重组抗体和用于制备所述抗体的基因片段。 构建能够产生具有优异的FCV中和活性的小鼠单克隆抗体的细胞系1D7，得到编码负责所述抗体的FCV特异性结合的V区的基因片段。 使用该基因片段和编码猫抗体恒定区的基因得到嵌合抗FCV重组抗体。 获得的重组抗体是一种新的抗体，可用于诊断，治疗和预防猫病毒感染，特别是猫杯状病毒感染，对猫的施用具有高度的安全性。

公开(公告)号：US5151023A

公开(公告)日：1992-09-29

申请号：US344911

申请日：1989-04-27

申请人： Syoji Kuzuhara ,  Koichi Odo ,  Kyosuke Mizuno

发明人： Syoji Kuzuhara ,  Koichi Odo ,  Kyosuke Mizuno

IPC分类号： C12N7/04 ,  A61K39/29 ,  A61P31/12

CPC分类号： A61K39/29 ,  A61K39/12 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/57 ,  A61K2039/70 ,  C12N2730/10134 ,  C12N2770/32434

摘要： A hepatitis A, B-combined adjuvanted vaccine is disclosed in this application, said vaccine comprising an inactivated hepatitis A virus antigen, a hepatitis B virus surface antigen and an adjuvant. The present vaccine is obtained by causing the antigens to be adsorbed to the adjuvant. According to the present invention, the infection associated with hepatitis A virus and with hepatitis B virus can be prevented without causing any interference due to the mixing of these antigens and any severe side-effects, and the anti-hepatitis A virus antibody titer is greatly enhanced by the mixing.

公开(公告)号：US5059542A

公开(公告)日：1991-10-22

申请号：US420531

申请日：1989-10-12

申请人： Takenori Hirai ,  Hirotaka Ihara ,  Chuichi Hirayama ,  Haruo Fuzita ,  Munehiro Saisho

发明人： Takenori Hirai ,  Hirotaka Ihara ,  Chuichi Hirayama ,  Haruo Fuzita ,  Munehiro Saisho

IPC分类号： G01N33/544 ,  A61K9/16 ,  C08B37/00 ,  C08F8/28 ,  G01N33/543 ,  G01N33/548

CPC分类号： A61K9/1641 ,  A61K9/1652 ,  C08G69/36 ,  G01N33/54313

摘要： An artificial carrier particle comprising an anionic polymer and a synthetic polyamino acid having at least one carboxylic group and at least one amino group in its side chain, the complex being insolubilized by an aldehyde crosslinking agent. The artificial carrier particle is useful in immunoassay, in particular, particle immunoassay. The artificial carrier particles are obtained by preparing an aqueous solution containing an anionic polymer and a synthetic polyamino acid comprising at least one free carboxyl group and at least one free amino group in its side chain, adjusting the pH of the solution to 3.5 to 9.5 at room temperature or at progressively increasing temperature under stirring to form solution particles of a desired particle size, and insolubilizing the particles by an aldehyde crosslinking agent.

公开(公告)号：US4725547A

公开(公告)日：1988-02-16

申请号：US764132

申请日：1985-08-09

申请人： Kuniaki Sakamoto ,  Kunio Ohkuma ,  Tetsuo Kawahara ,  Mitsuo Sakoh

发明人： Kuniaki Sakamoto ,  Kunio Ohkuma ,  Tetsuo Kawahara ,  Mitsuo Sakoh

IPC分类号： C12N15/09 ,  A61K39/205 ,  C12N7/00 ,  C12N7/02 ,  C12R1/91 ,  A61K39/12

CPC分类号： C12N7/00 ,  A61K39/12 ,  A61K39/205 ,  A61K2039/5252 ,  C12N2760/20134 ,  C12N2760/20151

摘要： Disclosed is a method for the purification of rabic virus, which comprises subjecting a solution containing the rabic virus to column chromatography using, as a gel for chromatography, a sulfuric acid ester of cellulose or a crosslinked polysaccharide. The method can provide highly purified rabic virus which is useful for obtaining an effective vaccine against rabies.

摘要翻译： 公开了一种用于纯化狂犬病毒的方法，其包括使用含有所述狂犬病病毒的溶液进行柱色谱，使用色谱法作为凝胶进行纤维素或交联多糖的硫酸酯。 该方法可以提供高度纯化的狂犬病病毒，其可用于获得针对狂犬病的有效疫苗。

公开(公告)号：US4725546A

公开(公告)日：1988-02-16

申请号：US764130

申请日：1985-08-09

申请人： Kuniaki Sakamoto ,  Isao Gotoh ,  Tetsuo Kawahara ,  Mitsuo Sakoh

发明人： Kuniaki Sakamoto ,  Isao Gotoh ,  Tetsuo Kawahara ,  Mitsuo Sakoh

IPC分类号： C12N15/09 ,  A61K39/12 ,  C12N7/00 ,  C12N7/02 ,  C12R1/91

CPC分类号： C12N7/00 ,  A61K39/12 ,  A61K2039/5252 ,  C12N2770/24134 ,  C12N2770/24151

摘要： Disclosed is a method for the purification of Japanese encephalitis virus, which comprises subjecting a solution containing the Japanese encephalitis virus to column chromatography using, as a gel for chromatography, a sulfuric acid ester of cellulose or a crosslinked polysaccharide. The method can provide highly purified Japanese encephalitis virus, which is useful for obtaining an effective vaccine against Japanese encephalitis.

摘要翻译： 公开了用于纯化日本脑炎病毒的方法，其包括使用含有日本脑炎病毒的溶液进行柱色谱，使用作为色谱用凝胶的纤维素或交联多糖的硫酸酯。 该方法可以提供高纯度的日本脑炎病毒，其可用于获得针对日本脑炎的有效疫苗。

公开(公告)号：US08759018B2

公开(公告)日：2014-06-24

申请号：US13030249

申请日：2011-02-18

申请人： Tomoko Ono ,  Shinichiro Watanabe ,  Fumio Furusaki ,  Ko Igami

发明人： Tomoko Ono ,  Shinichiro Watanabe ,  Fumio Furusaki ,  Ko Igami

IPC分类号： C12Q1/56 ,  G01N33/86

CPC分类号： C12Q1/37 ,  G01N33/573 ,  G01N33/6893 ,  G01N2333/755 ,  G01N2333/96486 ,  G01N2800/32 ,  Y10T436/106664

摘要： A method for determining an appropriate treatment option for a patient who has been diagnosed with disseminated intravascular coagulation (DIC) but who may have thrombotic thrombocytopenic purpura (TTP), by analyzing the amount and/or enzyme activity of a von Willebrand factor (vWF)-cleaving protease (ADAMTS13) and the amount of vWF in a patient that has been diagnosed with DIC is disclosed. Using the method of the present invention, a differential diagnosis of patients with thrombotic thrombocytopenic purpura (TTP) can be made from among patients diagnosed with DIC, which could not previously be distinguished on the basis of only clinical findings or known markers. Also disclosed is a kit for determining an appropriate treatment option, the kit comprising an antibody or a fragment thereof which specifically binds to ADAMTS13.

摘要翻译： 通过分析血管性血友病因子（vWF）的量和/或酶活性，确定已被诊断患有弥漫性血管内凝血（DIC）但可能具有血栓性血小板减少性紫癜（TTP）的患者的适当治疗选择的方法， 披露蛋白酶（ADAMTS13）和已诊断患有DIC的患者中的vWF量。 使用本发明的方法，可以从诊断为DIC的患者中进行血栓性血小板减少性紫癜（TTP）患者的鉴别诊断，以前不能仅基于临床发现或已知的标记来区分。 还公开了用于确定适当治疗选择的试剂盒，该试剂盒包含特异性结合ADAMTS13的抗体或其片段。

公开(公告)号：US08258264B2

公开(公告)日：2012-09-04

申请号：US10552369

申请日：2004-04-08

申请人： Rikiichi Tagawa ,  Yoshihiro Hayase ,  Kota Maemura ,  Hisashi Tanigawa

发明人： Rikiichi Tagawa ,  Yoshihiro Hayase ,  Kota Maemura ,  Hisashi Tanigawa

IPC分类号： C07K1/00 ,  C07K14/00 ,  C07K16/00 ,  C07K17/00

CPC分类号： C07K14/76 ,  A61K38/38 ,  B01D61/147

摘要： An albumin preparation may be produced efficiently on a commercial basis that has reduced possibility of contamination of infectious viruses and has high safety and stability. The process according to the present invention comprises a step of filtration of a serum albumin-containing solution with a virus-removing membrane preferably with a pore size of 10 to 20 nm. In particular, said filtration is performed before heat treatment for inactivation of viruses. In a more preferable embodiment, said serum albumin-containing solution is treated with an anion exchanger and/or a prefilter before a step of said filtration.

摘要翻译： 可以商业上有效地生产白蛋白制剂，其具有降低的感染性病毒污染的可能性并且具有高的安全性和稳定性。 根据本发明的方法包括用优选具有10至20nm的孔径的病毒除去膜过滤含血清白蛋白的溶液的步骤。 特别地，所述过滤在用于灭活病毒的热处理之前进行。 在更优选的实施方案中，所述含血清白蛋白的溶液在所述过滤步骤之前用阴离子交换剂和/或预过滤器处理。